Literature DB >> 11742810

Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts.

B C McKaig1, K Hughes, P J Tighe, Y R Mahida.   

Abstract

Intestinal strictures are frequent in Crohn's disease but not ulcerative colitis. We investigated the expression of transforming growth factor (TGF)-beta isoforms by isolated and cultured primary human intestinal myofibroblasts and the responsiveness of these cells and intestinal epithelial cells to TGF-beta isoforms. Normal intestinal myofibroblasts released predominantly TGF-beta(3) and ulcerative colitis myofibroblasts expressed both TGF-beta(1) and TGF-beta(3), whereas in myofibroblast cultures from fibrotic Crohn's disease tissue, there was significantly lower expression of TGF-beta(3) but enhanced release of TGF-beta(2). These distinctive patterns of TGF-beta isoform release were sustained through several myofibroblast passages. Proliferation of Crohn's disease myofibroblasts was significantly greater than that of myofibroblasts derived from normal and ulcerative colitis tissue. In contrast to cells from normal and ulcerative colitis tissue, neutralization of the three TGF-beta isoforms did not affect the proliferation of Crohn's disease intestinal myofibroblasts. Studies on the effect of recombinant TGF-beta isoforms on epithelial restitution and proliferation suggest that TGF-beta(2) may be the least effective of the three isoforms in intestinal wound repair. In conclusion, the enhanced release of TGF-beta(2) but reduced expression of TGF-beta(3) by Crohn's disease intestinal myofibroblasts, together with their enhanced proliferative capacity, may lead to the development of intestinal strictures.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11742810     DOI: 10.1152/ajpcell.00048.2001

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  52 in total

1.  Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.

Authors:  Dov Wengrower; Giuliana Zanninelli; Giovanni Latella; Stefano Necozione; Issa Metanes; Eran Israeli; Joseph Lysy; Mark Pines; Orit Papo; Eran Goldin
Journal:  Can J Gastroenterol       Date:  2012-01       Impact factor: 3.522

2.  Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis.

Authors:  Jennifer S Davids; Adelaide M Carothers; Beatrice C Damas; Monica M Bertagnolli
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

Review 3.  Colonic subepithelial myofibroblasts in mucosal inflammation and repair: contribution of bone marrow-derived stem cells to the gut regenerative response.

Authors:  Akira Andoh; Shigeki Bamba; Yoshihide Fujiyama; Mairi Brittan; Nicholas A Wright
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

Review 4.  Wound healing and fibrosis in intestinal disease.

Authors:  F Rieder; J Brenmoehl; S Leeb; J Schölmerich; G Rogler
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

5.  Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling.

Authors:  Jurgen J W Mulsow; R William G Watson; John M Fitzpatrick; P Ronan O'Connell
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

Review 6.  Inflammatory bowel disease: Moving toward a stem cell-based therapy.

Authors:  Giacomo Lanzoni; Giulia Roda; Andrea Belluzzi; Enrico Roda; Gian Paolo Bagnara
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

7.  Outcome and complications of endoscopic balloon dilatations in various types of ileocaecal and colonic stenosis in patients with Crohn's disease.

Authors:  Alexander F Hagel; Anna Hahn; Wolfgang Dauth; Klaus Matzel; Peter C Konturek; Markus F Neurath; Martin Raithel
Journal:  Surg Endosc       Date:  2014-05-23       Impact factor: 4.584

8.  Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression.

Authors:  C Bourgier; V Haydont; F Milliat; A François; V Holler; P Lasser; J Bourhis; D Mathé; M-C Vozenin-Brotons
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

9.  Oral administration of transforming growth factor-β1 (TGF-β1) protects the immature gut from injury via Smad protein-dependent suppression of epithelial nuclear factor κB (NF-κB) signaling and proinflammatory cytokine production.

Authors:  Sheng-Ru Shiou; Yueyue Yu; Yuee Guo; Maria Westerhoff; Lei Lu; Elaine O Petrof; Jun Sun; Erika C Claud
Journal:  J Biol Chem       Date:  2013-10-15       Impact factor: 5.157

10.  Smad3 knock-out mice as a useful model to study intestinal fibrogenesis.

Authors:  Giuliana Zanninelli; Antonella Vetuschi; Roberta Sferra; Angela D'Angelo; Amato Fratticci; Maria Adelaide Continenza; Maria Chiaramonte; Eugenio Gaudio; Renzo Caprilli; Giovanni Latella
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.